Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MMP9 | P14780 | 14/20 | 0.44 |
| ▸ | MMP13 | P45452 | 14/20 | 0.44 |
| ▸ | MMP1 | P03956 | 13/20 | 0.44 |
| ▸ | ADAM17 | P78536 | 12/20 | 0.44 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | TRPM8 | Q7Z2W7 | 3/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | HTT | P42858 | 1/20 | 0.39 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1098142 | 0.91 | KDM4E (0.51) | MMP9MMP13MMP1ADAM17CYP11B1 | |
| SCHEMBL1099070 | 0.82 | PTGER2 (0.46) | MMP9MMP13MMP1ADAM17CYP11B1 | |
| SCHEMBL1098774 | 0.80 | KMT2A (0.44) | MMP9MMP13MMP1ADAM17CYP11B1 | |
| SCHEMBL1098446 | 0.80 | TRPM8 (0.44) | CYP11B1TRPM8LMNAHTTNPSR1 | |
| SCHEMBL1098445 | 0.79 | TRPM8 (0.60) | MMP9MMP13MMP1ADAM17KDM4E | |
| SCHEMBL1098734 | 0.78 | TRPM8 (0.56) | TRPM8 | |
| SCHEMBL1097497 | 0.76 | TRPM8 (0.57) | MMP9MMP13MMP1ADAM17TRPM8 | |
| SCHEMBL1100218 | 0.76 | TRPM8 (0.57) | MMP9MMP13MMP1ADAM17CYP11B1 | |
| SCHEMBL28216245 | 0.76 | MEN1 (0.50) | MMP9MMP13MMP1ADAM17CYP11B1 | |
| SCHEMBL1100782 | 0.76 | PGR (0.50) | MMP9MMP13MMP1CYP11B1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9434711-B2 | Sulfonamides as TRPM8 modulators | JANSSEN PHARMACEUTICA, N.V. (BE) | 2016-09-06 | — | — | US | disclosed |
| US-20140315899-A1 | SULFONAMIDES AS TRPM8 MODULATORS | JANSSEN PHARMACEUTICA NV (BE) | 2014-10-23 | — | — | US | disclosed |
| US-8809327-B2 | Sulfonamides as TRPM8 modulators | JANSSEN PHARMACEUTICA, NV (BE) | 2014-08-19 | — | — | US | disclosed |
| EP-2183239-B1 | SULFONAMIDES AS TRPM8 MODULATORS | JANSSEN PHARMACEUTICA NV (BE) | 2012-08-22 | — | — | EP | disclosed |
| US-20120190674-A1 | SULFONAMIDES AS TRPM8 MODULATORS | BRANUM SHAWN T (US) | 2012-07-26 | — | — | US | disclosed |
| US-8153682-B2 | Sulfonamides as TRPM8 modulators | JANSSEN PHARMACEUTICA, NV (BE) | 2012-04-10 | — | — | US | disclosed |
| US-20090264474-A1 | SULFONAMIDES AS TRPM8 MODULATORS | JANSSEN PHARMACEUTICA, N.V. (BE) | 2009-10-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120190674-A1 | SULFONAMIDES AS TRPM8 MODULATORS | TRPM8, TRPM5, TRPM2 | MMP9 3504/4885MMP13 4507/4885MMP1 4838/4885 |
| US-20140315899-A1 | SULFONAMIDES AS TRPM8 MODULATORS | TRPM8, TRPM5, TRPM2 | MMP9 3504/4885MMP13 4507/4885MMP1 4838/4885 |
| US-20090264474-A1 | SULFONAMIDES AS TRPM8 MODULATORS | TRPM8, TRPM5, TRPM2 | MMP9 3504/4885MMP13 4507/4885MMP1 4838/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.